Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
A Look At Arcus Biosciences (RCUS) Valuation After Wells Fargo Downgrade And Shifting Analyst Sentiment [Yahoo! Finance]
Arcus Biosciences (NYSE:RCUS) was downgraded by analysts at Wells Fargo & Company from a "strong-buy" rating to a "hold" rating.
Arcus Biosciences (NYSE:RCUS) was given a new $23.00 price target on by analysts at Wells Fargo & Company.
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates [Yahoo! Finance]